Emergent BioSolutions | EBS - Umsatzkosten





Umsatzkosten Veränderung Datum
Acadia Pharmaceuticals USD 28.32M 3.52M 2026-06
Akebia Therapeutics USD 10.34M 441K 2025-12
ALKERMES USD 120.7M 47.44M 2026-06
Alnylam Pharmaceuticals USD 298.45M 87.33M 2026-06
Amarin USD 26.05M 1.41M 2025-12
ANI Pharmaceuticals USD 119.8M 5.3M 2026-06
BioMarin Pharmaceutical USD 276.29M 76.8M 2026-06
Coherus Biosciences USD 4.04M 324K 2025-12
Emergent BioSolutions USD 381.2M 226.1M 2023-06
Exelixis USD 20.66M 704K 2026-06
Glaxosmithkline GBP 1.88B 1.6B 2026-03
Heron Therapeutics USD 11.12M 795K 2025-12
Ionis Pharmaceuticals USD 2.74M 261K 2026-06
Ironwood Pharmaceuticals USD 29.83M 560K 2024-09
Lexicon Pharmaceuticals USD 201K 191K 2025-12
Lonza CHF 2.28B 189M 2025-06
Merck USD 3.14B 200M 2026-06
Moderna USD 93M 862M 2026-06
Myriad Genetics USD 63M 1.1M 2025-12
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Neurocrine Biosciences USD 39.4M 25.6M 2026-06
Pacira USD 58.49M 7.75M 2026-06
Pfizer USD 4.09B 498M 2026-06
PTC Therapeutics USD 39.61M 23.31M 2026-03
Sanofi EUR 3.02B 656M 2026-06
Sarepta Therapeutics USD 150.1M 40.64M 2026-06
United Therapeutics USD 99.5M 33.9M 2026-06
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12